Publication
Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.
Marie Christine Wesener, Uta Margareta Demel, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian Von Tresckow, Marcel Teichert, Amelie Boquoi, Tobias Holderried, Friederike Schmitz, Fabian Müller, Friedrich-Linus Rößiger, Michele Hoffmann, Natalie Schub, Natalia Tovar, Aina Oliver-Caldes, Nicolaus Kröger, Ben-Niklas Baermann, Stephan Bohl, David Fandrei, Vladan Vucinic, Irene Strassl, Friedrich Stölzel, Carlos Fernández De Larrea, Ulrich Keller, Antonia Busse, Maximilian Merz, Nico Gagelmann
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available